Harmony Biosciences Holdings (HRMY) Change in Accured Expenses (2019 - 2026)

Harmony Biosciences Holdings has disclosed Change in Accured Expenses across 8 years of filings, most recently posting -$46.2 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$46.2 million, down 746.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.3 million (up 87.11% YoY), and the FY2025 annual result was $68.0 million, up 476.27% from the prior year.
• Change in Accured Expenses came in at -$46.2 million for Q1 2026 at Harmony Biosciences Holdings, down from $52.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $52.5 million in Q4 2025 to a low of -$46.2 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $3.1 million (2023), against an average of $5.9 million.
• Across the five-year window, Change in Accured Expenses soared 535.86% in 2022 and sank 746.48% in 2026, its largest moves.
• Harmony Biosciences Holdings' Change in Accured Expenses stood at -$22.8 million in 2022, then jumped by 235.23% to $30.8 million in 2023, then plunged by 59.13% to $12.6 million in 2024, then soared by 317.11% to $52.5 million in 2025, then tumbled by 188.05% to -$46.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$46.2 million (Q1 2026), $52.5 million (Q4 2025), and $28.0 million (Q3 2025), per Business Quant data.